

<https://doi.org/10.59298/NIJBAS/2025/6.2.172400>

The Pharmacological Potential of Local Flora in HIV/AIDS Treatment

Bizimana Rukundo T.

Faculty of Biological Sciences Kampala International University Uganda

ABSTRACT

The global HIV/AIDS epidemic remains a significant public health challenge, particularly in sub-Saharan Africa where access to antiretroviral therapy (ART) is limited. Despite advances in pharmacological interventions, ART presents various drawbacks, including toxicity, resistance, cost, and limited accessibility in rural regions. Traditional medicine, especially the use of indigenous plants, continues to play a vital role in the management of HIV/AIDS and associated opportunistic infections. This paper explores the pharmacological potential of local flora in HIV/AIDS treatment, focusing on their traditional usage, phytochemical properties, mechanisms of antiviral action, and safety profiles. Southern African flora has shown promising anti-HIV activity in both ethnobotanical and preliminary in vitro studies. However, the lack of standardized research, clinical trials, and regulatory frameworks hinders their integration into mainstream healthcare. Bridging traditional knowledge with modern pharmacological research may yield affordable, accessible, and culturally accepted therapeutic options. This paper emphasizes the importance of comprehensive toxicological studies, standardized clinical trials, and collaborative research to fully realize the therapeutic value of local medicinal plants in the fight against HIV/AIDS.

Keywords: HIV/AIDS, Antiretroviral Therapy, Traditional Medicine, Local Flora, Phytochemistry, Ethnobotany.

INTRODUCTION

HIV (human immunodeficiency virus) is a retrovirus that attacks the body's immune system, specifically the CD4 T cells, resulting in the acquired immunodeficiency syndrome (AIDS). Infection with HIV or AIDS is a critical shortcoming for the immune system and potentially leads to opportunistic infections. The infection is root from the body's own resources. A slowly elevated virus-based infection starts its course prior to HIV-based disorder. HIV is the causative organism of AIDS, and its transmission depends on the continuous spread of the virus in body fluids coming in contact with the mucus, breach hematogenously into internal environments, and infect the T-helper lymphocytes (CD4 T cells). The virus in internal environments cannot be detected by the immunity, and new viruses are generated and released into internal fluids to start new infections in other body fluids. The minimum time between the time of predisposition to illness, and the time of disease onset in a subgroup of patients, if the risk factor was selected at random from the whole population, is usually taken to be the average incubation period. After a variable period of chronic HIV infection, illness occurs. The risk of HIV-positive persons eventually becoming ill with AIDS is 90% or more. The typical time course is 7 to 12 years, but many are rapid progressors and few are long-terminal. The compatibility with longstanding existence of adult HIV-positive patients is not yet understood. Haemophiliacs and recipients of blood products were prior to 1980 publicly healthy long-term HIV-positive persons. Pharmacotherapy consists of antiretrovirals, protease inhibitors, DNA injecting capsid inhibitors, and entry blockers. A few vaccines to prevent HIV

infection are being clinically tested; however, no attempt is reported on the cure of chronic HIV infection [1, 2].

Overview of Traditional Medicine

Traditional medicine, the oldest healing approach, is still relevant today and is practiced widely across continents. Defined as the sum of knowledge, skills and practices based on theories, beliefs and experiences of the different cultures, Traditional medicine is used to maintain health, as well as to treat and diagnose physical and mental illnesses. Different systems of traditional medicine, with their own healing practices and natural medicines, are being practiced across the African continent, including Ayurveda in India, natural medicine in China and Unani in the Middle East, Asia and Europe. The African continent has local traditional health systems used by communities independently or integrated into the health care systems. Traditional medicine is generally based on knowledge and experiences passed down orally from one generation to the next. In many developing countries, including Zambia, the practice and use of traditional medicines predates the presence of modern health care systems and are still widely used to treat ailments, including HIV/AIDS related opportunistic diseases. Traditional healers describe a spirit possession as the source of their herbal knowledge, which is said to have been handed down by the ancestors. Traditional healers are highly revered for their knowledge of the flora, and potent plants in particular, and are consulted in high regard when seeking treatment for illnesses thought to be linked to spiritual matters. The seek and use of modern health care systems is a slow process among many communities. Composite systems are adopted in which traditional health care practitioners and modern health care providers coexist. Definition wise, this term denotes a system of healing choices in which providers of diverse healing methods interact across the biomedical—traditional dichotomy. The two systems may be studied in their social or cultural settings with emphasis on how either of them or both are consulted by individual seek and use plants, animal and mineral products or biomedical treatments. The approach is becoming more popular in health care research in developing countries with the recognition of the role of traditional medicine in health care delivery. In some cases the consultation of traditional healers predates the consult of modern health care providers. In Zambia, consultations for HIV/AIDS treatment involved traditional healers before modern health care providers. The wide use of traditional medicines and their adoption in health care delivery systems has not been adequately addressed. Parts of the health care programmes are defined by an array of medicines and healing rituals provided by traditional healers/health care practitioners. The cumulative effect of this limited academic focus is that there is little information on the plants used to manage HIV/AIDS treatment, the knowledge and skills behind it, as well as the values that underpin it, and the expectation of clients or society from the practitioners [3, 4].

Local Flora: An Introduction

HIV/AIDS is a serious problem, and its treatment is not curative. Antiretroviral therapy (ART) is a combination of drugs that suppress HIV replication and induces long-term viral remission. ART can improve health status and life expectancy, but it does not cure infection and has many undesirable effects. The treatment must be done chronically, and it induces drug resistance that increases viral load and disease progression because of the resulting unkind safety profile environment. The availability of treatment is unequal and inaccessible in many rural areas; also, it is inconvenient and varying due to interruption of treatment and storage issues. The drugs used in ART are artificial and expensive, and they are quarantined for intellectual property protection preventing innovation in HIV drug research and production. Additionally, ART can cause toxicity, leading to cardiovascular issues, hepatotoxicity, lipoatrophy, kidney toxicity, central nervous system problems, and even death in the long-term. Drugs of plant origin produce medicinal effectiveness in many areas, including but not limited to anti-infective, chemopreventive, anti-neoplastic, immunomodulating, anti-inflammatory, and analgesic. Medicinal plants can be used instead of standard treatment in the case of the cheaper commodification and availability of arboreal flora. Southern Africa is notable for having a wide variety of local flora. Some of them were explored for anti-HIV activity and are worth noting [5, 6].

Phytochemistry of Local Plants

In Africa, demand for complementary medicines for HIV/AIDS treatment is increasing due to limited and unaffordable ART. Half of new global infections occur here, with few pharmacotherapeutic options available that offer affordability, safety, and efficacy. Some ART patients develop opportunistic infections, leading to treatment failures and disease progression. There is growing interest in using plants for anti-HIV therapies, supported by infodemic data. Southern African plants are notably cited for their anti-viral properties, including claims for their use against HIV/AIDS. Initial investigations have identified therapeutic successes among certain plants, prompting the need for further research into their chemical

and economic attributes. Despite their traditional application for viral diseases, modern scientific studies on these plants' anti-HIV activities remain scarce. Reviews classify plant species by location and family, detailing traditional uses and anti-HIV potential. However, there is limited current literature on the active compounds in these species and no comprehensive reviews of their anti-HIV properties. A deeper investigation into the most characterized species and their action mechanisms could enhance understanding of their therapeutic roles in managing HIV/AIDS [7, 8].

Mechanisms of Action

The virus may enter host cells via several pathways dependent on the presence or absence of CD4 receptors and co-receptors. Once inside the cytoplasm, the virion disassembles, releasing its genetic material and enzymes. After uncoating, reverse transcription produces double-stranded DNA from the RNA genome using the reverse transcriptase enzyme. The dsDNA enters the cell nucleus where it is integrated into the host cell genome by integrase. This integrated form of the provirus is thereby able to commandeer the host cell's machinery and produce new copies of the virus. Proteins of the progeny virus assemble around the viral genome and enzymes in the cytoplasm, bud from the cell, and are released from the host cell, eventually infecting new cells. HIV can be targeted at any step in the replication cycle using small molecules, usually in the form of drugs. Several viral and cellular targets have been identified as the main mode of action of different types of drugs. Viral targets are either proteins encoded by the HIV genome or the RNA genome itself. As the virus uses the host cell for most of the replication cycle, recognition is limited to only a few enzymes produced solely by the virus. The currently used antiviral drugs for the therapy of HIV/AIDS can be classified into six classes based on their targets in the HIV replication cycle: Entry inhibitors, reverse transcriptase inhibitors, integrase inhibitors, protease inhibitors, maturation inhibitors, and nucleic acid-based inhibitors. Natural products and phytochemicals have been well known as easy sources of template or lead killing agents against various diseases. A number of plant-derived products and their derivatives have gained importance in chemoprevention and/or therapy of a variety of human diseases owing to their potent biological activities. Globally, nearly 80% of the population depends on herbal medicines for their health care. Traditional use of plants in the management of HIV/AIDS has opened avenues for the phytochemical examination of local flora [9, 10].

Ethnobotanical Studies

Scientific research and laboratory testing have been conducted on plants used traditionally to treat HIV/AIDS and associated ailments, leading to varying degrees of success. To identify suitable candidates, literature reviews are considered of utmost importance. Such research seems to be lacking, especially for the southern African region. With the escalating number of individuals becoming HIV-infected, the need for research interests in the pharmacological potential of local flora for treating HIV/AIDS is becoming ever more urgent. Traditional healers and herbal medicine practitioners use local plants to treat a host of ailments, including HIV/AIDS. Some of these plants have been screened in vitro using various anti-HIV pharmacological approaches. The average number of studies on HIV using southern African plant species is low. However, as new treatment options need to be explored, the time may be right for renewed efforts. Forming a collaborative approach between traditional, herbal, and scientific local and international researchers is recommended. Combining indigenous knowledge with scientific knowledge and experience may lead to verifying or nullifying traditional wisdom, while, in the best-case scenario, enabling the formulation of novel patentable molecules that will treat HIV/AIDS, or at least some of the symptoms thereof [11, 12].

Clinical Trials and Research

Various investigations on selected plant extracts' ability to inhibit HIV-1 through different mechanisms of action were conducted. On the aircraft, Zimbabwean plants *Libangala* = (*Brachystegia spiciformis*), *Pachypodium* = *saundersii*, and *Siphonochilus* = *aethiopicus* possess high anti-HIV-1 activity. Dose-dependent inhibition and no cytotoxicity were observed with a semi-purified extract from Zambian plants, especially *Cymbopogon* = *schoenanthus* and *Pericopsis* = *angolensis*, against three subtypes of HIV-1. Efficacy was also demonstrated on the dock with proanthocyanidines from *G. congoensis* and *L. latifolius*, and *Embelia* = *schimperae*, *Wrightia* = *tinctoria* and *B. edulis* inhibited HIV replication in C8166 cells. *B. prionotes* and *M. lucida* extracts prevented HIV-infection in CEM-SS cells. In tissues, A2-1656, T1-24650, and S1-14612 extracts possessed anti-HIV-1 activity, indicating their potential to be pursued as sources for the development of antiviral drugs. The *P. obovatus*, *L. zeylanica*, and *C. zeylanicum* extracts exhibited a high percentage of significant inhibition of RT activity of HIV-1 after 5 min (46, 48 and 53%, respectively). The former two showed dose-dependence inhibition of the RT activity of HIV-1, MSMWE032-10A exhibited the highest anti-viral activity, while the IC₅₀ value of the *C. glomerata* extract against the Bringel's virus was found to be 4120 µg/ml. Setting up the tradition against isolation

from each other and sudden divorce leads to various disasters on continuous development. Legislation of the West related to mentalism and individualism put all older generations in dismay, permitting utter freedom to extract and persecute the wisdom behind a proper position. Ultimately, continuous exchange between objects and belief collected during the natural development of the tribe devised folk medicine. Prohibition according to regulation was naturally trespassed. Anticipated production rules and gradual change in delays eventually dissolved the terrene matters. The text recognized a non-transmissible form of competitive space claiming the right of possession under semi physical treatment. The Bangladesh specter delineate branch for a probable common ancestor and FAN. The true responsible form of morbidity for population explosions posterior to anti-ritual input, ultra citation, and preparation revelation was reconstructed. Seeming calamities anticipated both in toward and deferred effect pointed toward a kind moral perception incapable of foolishness but refraining, remorseful and cruel.

Safety and Toxicity of Local Flora

Studies have shown that the antiretroviral and anticancer activities of plants may be ascribed to phytocompounds or extracts that must be explored. Investigated plants must be assessed for their safety or toxicity to guard against side effects. In light of this, a thorough literature review on the possible toxicity or safety of plants highlighted in this study is required so as to identify those that had been investigated previously for toxicity and report on safety studies not yet investigated. The aim is to gather information on the possible safety and toxicities of plants listed in this study and report on those that have undergone any previous safety studies. A total of 45 plants were found to hold promise for the treatment of HIV/AIDS. Several plants possess multiple antiretroviral, anticancer, and antiviral actions. Thirty-nine plants have not yet been studied for toxicity, side effects, or safety, while at least six are documented to possess toxic effects and side effects. The plants with potential toxic effects include: *Agathosma crenulata*; *Buddleja salviifolia*; *Canthium inerme*; *Diospyros mespiliformis*; *Diospyros thunbergii*; *Lippia javanica*; *Moringa oleifera*; *Nymphaea*, and *Salvia* sage. Reports of some other plants used traditionally for South African HIV/AIDS treatment medication but not listed in this study due to lack of documented activity include *Aloe*, *Calluna vulgaris*, *Croton gratissimus*, and *Sutherlandia frutescens*. Some of these have anti-HIV effects and are currently used in combination with established drugs in trials against HIV/AIDS. *Croton gratissimus* and *Sutherlandia frutescens* exert cell toxicity against healthy cells and warrant further attention to minimize safety concerns [13, 14].

Regulatory Considerations

The provision of medications for effectively treating any disease, and particularly for HIV/AIDS, is governed by strict regulations under the Therapeutic Goods Act in Australia. The Therapeutic Goods Administration (TGA) plays a crucial role in overseeing and enforcing these regulations. Several key hazards and challenges have been identified in this domain, which include Safety (toxicity), Quality (formulation, storage, stability), and Efficacy (effectiveness) of the treatments provided. The evaluation of safety involves comprehensive preclinical toxicity studies conducted in various mammals, including commonly used species such as rats and rabbits. Such studies are essential as they help to establish safe dose limits that can be utilized during human trials, thereby ensuring participant safety. In addition to safety evaluation, the assessment of quality requires meticulous studies on stability that can take up to two years to complete. These studies investigate the effects of formulation, packaging, and storage conditions on the medications to ensure their integrity and efficacy over time. Moreover, the production processes for these medications must always follow validated and standardized procedures. This is critical to ensure batch consistency, which in turn meets the quality specifications set forth by regulatory authorities. Rigorous testing during the manufacturing stages is mandated to uphold these quality standards. The TGA has established that all three aspects—safety, quality, and efficacy—must meet stringent criteria that are assessed over several years prior to granting marketing approval. In addition to these regulatory processes, collaboration between the TGA and the National Institute of Health fosters more efficient and streamlined processes in medication regulation and approval. Meanwhile, in the United States, there are ongoing concerns surrounding the treatments available for HIV/AIDS. These concerns include the vital need for effective antiviral agents, the toxicity of current treatments particularly in major ethnic groups, and detailed analyses of potency and purity of these medications. However, the situation is complicated by issues of commercial confidentiality, which significantly hampers the sharing of crucial data related to these treatments [15, 16].

Case Studies

Statistics on HIV in southern Africa illustrate its impact on vulnerable societies. While the region has seen a decline in infections over the past decades, anti-retroviral therapy (ART) has been pivotal in enhancing the lives of those affected. However, ART faces challenges such as drug resistance, toxicity,

limited availability, and an inability to cure. These issues are particularly pertinent in poorer communities. Consequently, there has been increased research into local flora and traditional medicinal plants to discover new anti-HIV compounds. The number of studies has risen, focusing on various plant species through systematic reviews and original literature sources. Searches using terms like "HIV", "medicinal plants", "Africa", and "anti-viral" were conducted, with criteria emphasizing plants' documented traditional use against infectious diseases or HIV, scientific identification, native status to southern Africa, and acceptable anti-HIV activity levels. Many southern African plants have traditionally been used for viral infections, with laboratory investigations validating their potential against HIV. These plants may lead to effective anti-HIV agents. Further research to elucidate their mechanisms of action remains crucial for HIV/AIDS prevention and treatment [17, 18].

Future Directions in Research

More systematic studies are warranted to explore unexplored wilderness for plants with novel compounds with anti-HIV activity. Recent research has provided important insights into the potential mechanism of action of compounds with anti-HIV activity. These efforts are expected to lead to a better understanding of the compounds leading to the design and synthesis of more potent anti-HIV agents. Moreover, development of semi-synthetic drugs with better pharmacokinetics and pharmacodynamics behavior for in vivo studies is warranted. Validation of traditional medicinal practices, including long term observations of their safety and efficacy is warranted. Search for more active and potent leads from the local flora, especially for new targets like integrase and host factors is warranted. Mathematical modelling of the geography/climate/altitude/soil/pH/ozone/organic carbon based plant distribution data is warranted to identify new and unexplored areas of pseudo-tropical forests, analogies of McKinnley and Mount Everest IPAs that may harbor plants with lead yields. Studies are warranted to identify flora with potential compounds for medication of treatment-emergent other viral infections (byproducts of HIV-1 body attacking retrotransposons) [19, 20].

Challenges In Utilizing Local Flora

HIV-related antiretroviral (ARV) therapy and prevention was introduced in many tropical regions almost 2 decades after the first drugs were utilized in developed countries. This is at a time when the virus has mutated and developed into complex variants as one of the mechanisms by which it has become more virulent and resistant to treatment. Nevertheless, the WHO still encourages countries in sub-Saharan Africa to utilize these drugs as its notice on eradication of AIDS will still be held based on wide access to ARVs and prevention methods in many developing countries of tropical regions. Even among advanced countries, HIV is still virulent with television documentaries showcasing this threat in developed countries. The relative lack of harmonization among countries' timeframes in offering new HIV drug formulations to the public made this susceptible to abuse by the HIV virus. Therefore, efforts should be made during treatment to encourage the exploration of local flora to search for more effective antivirals. Botoc has volunteered in search of local flora as many plants explored before have been involved in other activities like cosmetic treatment and dietary supplement. With respect to plants of Africa, although toxic plants (like *Abrus precatorius*), hallucinogenic ones, and plants used in traditional medicine can be controversial sources, they are rich in compounds with antiviral activities, where view of *Peltandra excisa* plant family as a potentially important source of immunosuppressive compounds. Although species like *Cassia alata*, *Croton tiglium* L, *Apocynum venetum*, and *Cardiospermum halicacabum* are poisonous in review of poisonous plants, their activities on other diseases like tuberculosis, malaria, and diabetes are subjected to scrutiny in quest for anti-HIV compounds. Hallucinogenic plants with intoxication and euphoria inducing activities like *Cannabis sativa* also deserve scrutiny for possible anti-HIV activity. Food supplements and edible plants like *Cucumis melo* species are relevant in view of their antiviral effectiveness. Available of molecular technique makes screening for a tuberculous fact 'anthracene' local flora of amenité's region easier in quest of discovering more effective antriretroviral agents against these variants [21, 22].

Integration with Conventional Treatments

The HIV/AIDS pandemic's impact on immune cells and the central nervous system has led to antiretroviral therapy (ART) and immune-based strategies. Increasing recognition of local flora's pharmacological potential has emerged, with traditional medicinal plants used in rural areas showing promising in vitro and in vivo results against HIV/AIDS. These plants have demonstrated immunomodulatory and anti-HIV activities through traditional remedies. The global shift toward "green medicine" seeks beneficial plant resources for human health, compensating for the synthetic agents' high costs and accessibility issues. Many HIV-1 mutations develop resistance to saquinavir, a first-generation protease inhibitor, while commercial antiretroviral medicines are expensive and less accessible due to

patent concerns. The stepwise mutations of HIV genes against similar-class drugs complicate treatment. There's an urgent need for new anti-HIV agents with varied characteristics and mechanisms. Nature provides safe and affordable healing options, reinforcing local healthcare. While antiretroviral drugs can reduce viral load, financial and political barriers limit their availability. In contrast, traditional medicine offers new drug candidates for HIV and related disorders, necessitating further research on folk species better known to local practitioners. Globally, plants used in traditional medicine have yielded bioactive compounds effective in reducing disease burden. Although the number of anti-HIV compounds from plants is gradually increasing, most remain untested against HIV-1, HIV-2, and SIV. The rising resistance of HIV-1 to antiretroviral drugs emphasizes the urgent need for treatments with natural products and their derivatives. Efforts through international collaboration aim to discover new antiviral agents, particularly targeting viral replication machinery and proteins. The WHO advocates for evaluating traditional ethno-medicines for HIV/AIDS management. Several plants have been identified as active against HIV, with over 75 plant extracts tested since 1991. Many preparations showed efficacy and low cytotoxicity, highlighting the potential of natural products in repressing HIV replication and progression [23, 24].

Public Health Implications

Scientific progress has enabled first-world and some developing countries to access innovative medicines for patients. However, many regions and populations in these nations struggle with inadequate treatment options due to clinical logistics or cultural incompatibility. South Africa, part of the BRICS alliance, has a relatively developed healthcare and pharmaceutical system, yet many regions worldwide still face challenges linked to geography, environment, history, and socio-political factors. Cultural beliefs significantly influence healthcare, as evidenced by South Africa's well-documented traditional medicine practices. The country's flora offers many potential compounds for herbal remedies used locally and abroad. Psychotropic plant use is a global health issue, particularly in South Africa, where legislation on psychoactive substances is difficult to enforce. Therefore, focusing on public health is crucial. Raising awareness about illegal traditional medicines and educating the public to prevent dangerous consumption is essential. Additionally, research on traditional medicines to register effective herbal alternatives and exploring synergistic combinations, administration techniques, and dosing could enhance the success of effective herbal treatments [25, 26].

CONCLUSION

The persistent burden of HIV/AIDS, particularly in resource-constrained regions, necessitates alternative and complementary therapeutic strategies beyond conventional antiretroviral therapy. Local flora, deeply embedded in traditional medical practices, presents a reservoir of bioactive compounds with significant pharmacological potential. Despite the promising anti-HIV activity reported in various ethnobotanical and preliminary in vitro studies, scientific validation through phytochemical profiling, safety assessments, and clinical trials remains critically insufficient. Addressing this gap requires a multidisciplinary approach that integrates traditional knowledge with modern biomedical research. Policies and regulatory frameworks must evolve to support collaborative efforts between traditional healers, researchers, and healthcare institutions. Such synergy can facilitate the development of safe, effective, and culturally appropriate plant-based therapies, enhancing HIV/AIDS treatment outcomes while preserving indigenous knowledge systems. Ultimately, recognizing and rigorously evaluating the therapeutic promise of local medicinal plants may contribute substantially to the global fight against HIV/AIDS.

REFERENCES

1. Gáspár Z, Nagavci B, Szabó BG, Lakatos B. Gut Microbiome Alteration in HIV/AIDS and the role of antiretroviral Therapy—A scoping review. *Microorganisms*. 2024 Nov 1;12(11):2221.
2. Kariya P, Shringarpure KS, Patel AG. Awareness and knowledge of HIV/AIDS in school going children of Surat, Gujarat. *Int J Comm Med Pub Health*. 2023 Aug;10:2821-6. [researchgate.net](https://www.researchgate.net)
3. Kankara SS, Nuhu AI, Bindawa KA, Haruna MR, Bello A, Abubakar IB. Indigenous traditional knowledge of medicinal plants used for the management of HIV/AIDS opportunistic infections in Katsina State, Nigeria. *Ethnobotany Research and Applications*. 2022 Jun 2;23:1-7. [ethnobotanyjournal.org](https://www.ethnobotanyjournal.org)
4. Ikinyom N, Lamwaka AV, Malagala AT, Ndyomugenyi EK. Ethnobotanical study of nutraceutical plants used to manage opportunistic infections associated with HIV/AIDS in Acholi sub-region, Northern Uganda. *Tropical Medicine and Health*. 2023 Sep 1;51(1):50. [springer.com](https://www.springer.com)

5. Richard K, Poli AN, Andrae-Marobela K, Tietjen I. Medicinal Plant and Traditional Knowledge-guided Strategies to Combat HIV Persistence. *Current HIV/AIDS Reports*. 2025 Dec;22(1):5. [\[HTML\]](#)
6. Narayanan A, Kieri O, Vesterbacka J, Manoharan L, Chen P, Ghorbani M, Ljunggren HG, Sällberg Chen M, Aleman S, Sönnernborg A, Ray S. Exploring the interplay between antiretroviral therapy and the gut-oral microbiome axis in people living with HIV. *Scientific Reports*. 2024 Aug 1;14(1):17820.
7. Ogidi OI, Emaikwu NG. Utilization methods and practices of herbal medicine in Africa. In *Herbal Medicine Phytochemistry: Applications and Trends 2024* Jul 10 (pp. 1367-1393). Cham: Springer International Publishing. [\[HTML\]](#)
8. Bareetseng S. The worldwide herbal market: trends and opportunities. *Journal ISSN*. 2022;2766:2276.
9. Chopra B, Dhingra AK. Natural products: A lead for drug discovery and development. *Phytotherapy Research*. 2021 Sep;35(9):4660-702.
10. Chaachouay N, Zidane L. Plant-derived natural products: a source for drug discovery and development. *Drugs and Drug Candidates*. 2024 Feb 19;3(1):184-207.
11. Inarmal N, Moodley B. Selected pharmaceutical analysis in a wastewater treatment plant during COVID-19 infection waves in South Africa. *Environmental Science: Water Research & Technology*. 2023;9(6):1566-76. rsc.org
12. van Wilgen BW, Wannenburg A, Wilson JR. A review of two decades of government support for managing alien plant invasions in South Africa. *Biological Conservation*. 2022 Oct 1;274:109741.
13. Otsuki K, Zhang M, Li W. Natural products against HIV latency. *Acupuncture and Herbal Medicine*. 2021 Sep 1;1(1):10-21.
14. Sharma R, Bhattu M, Tripathi A, Verma M, Acevedo R, Kumar P, Rajput VD, Singh J. Potential medicinal plants to combat viral infections: A way forward to environmental biotechnology. *Environmental Research*. 2023 Jun 15;227:115725. [\[HTML\]](#)
15. Rudge C, Ghinea N. Promoting the personal importation of therapeutic goods: recent legislative amendments to advertising regulations may impact consumer access and understanding. *Australian Health Review*. 2023 Feb 13;47(2):182-91.
16. Lim M, Devine A, Gray RT, Kwon JA, Hutchinson JL, Ong JJ. Lifetime cost of HIV management in Australia: an economic model. *Sexual Health*. 2022 Aug 30;19(6):517-24. publish.csiro.au
17. Attah AF, Fagbemi AA, Olubiyi O, Dada-Adegbola H, Oluwadotun A, Elujoba A, Babalola CP. Therapeutic potentials of antiviral plants used in traditional African medicine with COVID-19 in focus: A Nigerian perspective. *Frontiers in pharmacology*. 2021 Apr 26;12:596855. frontiersin.org
18. McGaw LJ, Omokhua-Uyi AG, Finnie JF, Van Staden J. Invasive alien plants and weeds in South Africa: A review of their applications in traditional medicine and potential pharmaceutical properties. *Journal of Ethnopharmacology*. 2022 Jan 30;283:114564. up.ac.za
19. Anjum F, Mohammad T, Almalki AA, Akhtar O, Abdullaev B, Hassan MI. Phytoconstituents and medicinal plants for anticancer drug discovery: Computational identification of potent inhibitors of PIM1 kinase. *Omics: A Journal of Integrative Biology*. 2021 Sep 1;25(9):580-90. [\[HTML\]](#)
20. Li P, Tedersoo L, Crowther TW, Dumbrell AJ, Dini-Andreote F, Bahram M, Kuang L, Li T, Wu M, Jiang Y, Luan L. Fossil-fuel-dependent scenarios could lead to a significant decline of global plant-beneficial bacteria abundance in soils by 2100. *Nature Food*. 2023 Nov;4(11):996-1006. essex.ac.uk
21. Saini R, Ali MI, Pant M, Warghane A. Current Status of Potential Antiviral Drugs Derived from Plant, Marine, and Microbial Sources. *Anti-Infective Agents*. 2024 Apr 1;22(2):61-73.
22. Zeedan GS, Abdalhamed AM. Antiviral Effects of Plant Extracts Used in the Treatment of Important Animal Viral Diseases. *World's Veterinary Journal*. 2021(4):521-33.
23. Hua Y, Dai X, Xu Y, Xing G, Liu H, Lu T, Chen Y, Zhang Y. Drug repositioning: Progress and challenges in drug discovery for various diseases. *European journal of medicinal chemistry*. 2022 Apr 15;234:114239. nih.gov

24. Yang KC, Lin JC, Tsai HH, Hsu CY, Shih V, Hu CM. Nanotechnology advances in pathogen-and host-targeted antiviral delivery: multipronged therapeutic intervention for pandemic control. *Drug Delivery and Translational Research*. 2021 Aug;11:1420-37. [springer.com](https://www.springer.com)
25. Ndhlovu PT, Omotayo AO, Otang-Mbeng W, Aremu AO. Commercialization potential of six selected medicinal plants commonly used for childhood diseases in South Africa: A review. *Sustainability*. 2021 Dec 24;14(1):177.
26. Mudau FN, Chimonyo VG, Modi AT, Mabhaudhi T. Neglected and underutilised crops: a systematic review of their potential as food and herbal medicinal crops in South Africa. *Frontiers in Pharmacology*. 2022 Jan 20;12:809866. [frontiersin.org](https://www.frontiersin.org).

CITE AS: Bizimana Rukundo T. (2025). The Pharmacological Potential of Local Flora in HIV/AIDS Treatment. NEWPORT INTERNATIONAL JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES,6(2):17-24.
<https://doi.org/10.59298/NIJBAS/2025/6.2.172400>